Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...

Merck&Co., Inc., an American multinational biopharmaceutical company, has entered into an agreement to acquire the rights to the experimental drug HRS-5346, developed by China's Jiangsu Hengrui ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.